Bioaffinity Technologies Inc (BIAF) Stock Price, Quote & News

Company Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indica...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 210 698 5334

Website: bioaffinitytech.com

Address:

3300 Nacogdoches Road, Suite 216, San Antonio, United States

Lyn30 Aug. 24 at 2:47 PM

$BIAF OS 592k post split Time to

0 · Reply

Green_backs Aug. 24 at 2:47 PM

$BIAF this thing is so under valued. Already the same revenue as all of last year before the new deal

0 · Reply

vicdavis Aug. 24 at 2:21 PM

$BIAF A turd at any price smells as bad

0 · Reply

rihtim Aug. 24 at 1:47 PM

$BIAF AvMEDICAL ile yeni bir dağıtım anlaşması aracılığıyla federal sağlık kurumlarında CyPath® akciğer erişimini genişletiyor.

0 · Reply

rihtim Aug. 24 at 1:46 PM

$BIAF CyPath Lung hakkında pulmonologlar ve diğer sağlık profesyonelleriyle yaptığınız konuşmalar, akciğer kanseri için yüksek performanslı, invaziv olmayan bir test olarak konumunu her zaman güçlendirir. AAIP'teki güçlü katılım, CyPath Lung'un arkasındaki artan ivmeyi ve satış ekibimizin testi daha fazla hekim ve hastaya ulaştırmak için yaptıkları önemli çalışmaları yansıtıyor.

0 · Reply

rihtim Aug. 24 at 1:45 PM

$BIAF A big congratulations to our outstanding team as they wrap up #AABIP2026!

0 · Reply

rihtim Aug. 24 at 1:43 PM

$BIAF Kısa Pozisyon Alan Hisse Senedi Yüzdesi 0.28%

0 · Reply

STACKD0E Aug. 24 at 1:14 PM

$BIAF 👀

0 · Reply

AlwaysABullNeverABear Aug. 24 at 1:12 PM

$BIAF LFG

0 · Reply

DekmarTrades Aug. 24 at 1:04 PM

A lot of weird gap ups just happened. $GRML $VCIG $BIAF $INCR

1 · Reply

bioAffinity Technologies Inc trading halted, news pending

2026-08-20T12:05:09.000Z - 4 days ago

BioAffinity Technologies announces 1-for-15 reverse stock split

Aug 20, 2026, 8:00 AM EDT - 4 days ago

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

2026-08-18T12:05:35.000Z - 6 days ago

BioAffinity Technologies, AvMEDICAL announce distribution agreement for CyPath

Aug 18, 2026, 8:00 AM EDT - 6 days ago

bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung

2026-08-17T07:36:26.000Z - 7 days ago

BioAffinity prices 8.46M shares at 47.27c in private placement

2026-08-16T13:00:19.000Z - 8 days ago

BioAffinity Technologies announces closing of $4M private placement offering

Aug 14, 2026, 11:45 AM EDT - 10 days ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Aug 14, 2026, 11:07 AM EDT - 10 days ago

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Aug 13, 2026, 10:00 AM EDT - 11 days ago

WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Aug 13, 2026, 9:07 AM EDT - 11 days ago

bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Aug 7, 2026, 8:30 AM EDT - 17 days ago

bioAffinity Technologies Earnings release: Q2 2026

Aug 7, 2026, 8:30 AM EDT - 17 days ago

bioAffinity Technologies Quarterly report: Q2 2026

2026-08-07T12:06:04.000Z - 17 days ago

BioAffinity Technologies reports Q2 EPS (64c) vs ($5.07) last year

Aug 7, 2026, 8:00 AM EDT - 17 days ago

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

2026-07-27T12:15:08.000Z - 4 weeks ago

BioAffinity announces publication of clinical review on CyPath Lung

Jul 27, 2026, 8:08 AM EDT - 4 weeks ago

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

2026-07-22T12:16:50.000Z - 4 weeks ago

BioAffinity Technologies announces collaboration with Pictor

Jul 22, 2026, 8:08 AM EDT - 4 weeks ago

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD

2026-07-07T12:55:34.000Z - 6 weeks ago

BioAffinity Technologies’ CyPath Lung diagnostic sales double in Q2

Jul 7, 2026, 8:46 AM EDT - 6 weeks ago

bioAffinity Technologies' Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

2026-06-22T12:09:49.000Z - 2 months ago

BioAffinity will present preclinical findings on small interfering RNAs

Jun 22, 2026, 8:00 AM EDT - 2 months ago

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

Jun 18, 2026, 2:54 PM EDT - 2 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering

Jun 18, 2026, 1:16 PM EDT - 2 months ago

bioAffinity Technologies Announces Closing of $3.2 Million Offering

Jun 17, 2026, 10:41 AM EDT - 2 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering

2026-06-17T13:30:10.000Z - 2 months ago

BioAffinity Technologies prices 4M shares at 80c in public offering

Jun 17, 2026, 9:25 AM EDT - 2 months ago

bioAffinity Technologies Announces Pricing of $3.2 Million Offering

2026-06-16T12:12:01.000Z - 2 months ago

BioAffinity announces webinar for program to advance veteran lung health

Jun 16, 2026, 8:06 AM EDT - 2 months ago

bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans

Jun 16, 2026, 8:00 AM EDT - 2 months ago

bioAffinity Technologies Registration statement: Registration filing

2026-06-12T21:16:36.000Z - 2 months ago

BioAffinity Technologies files to sell 2.63M shares of common stock

Jun 12, 2026, 8:00 AM EDT - 2 months ago

bioAffinity Technologies Registration statement: Registration filing

2026-06-02T13:22:44.000Z - 2 months ago

BioAffinity Technologies announces SAB to host webinar on CyPath Lung

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies' Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

2026-05-27T14:25:36.000Z - 3 months ago

BioAffinity Technologies announces notification of Mexico patent allowance

May 27, 2026, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology

2026-05-12T13:24:11.000Z - 3 months ago

BioAffinity says CyPath Lung test unit sales achieved monthly record in April

May 12, 2026, 9:15 AM EDT - 3 months ago

bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026

2026-05-08T17:10:03.000Z - 3 months ago

BioAffinity Technologies reports Q1 EPS (81c) vs. ($4.80) last year

May 8, 2026, 8:30 AM EDT - 3 months ago

bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung

May 8, 2026, 8:30 AM EDT - 3 months ago

bioAffinity Technologies Earnings release: Q1 2026

May 8, 2026, 8:30 AM EDT - 3 months ago

bioAffinity Technologies Quarterly report: Q1 2026

2026-04-30T21:19:40.000Z - 4 months ago

BioAffinity Technologies files to sell 497,483 shares of common stock for holder

Apr 30, 2026, 8:00 AM EDT - 4 months ago

bioAffinity Technologies Registration statement: Registration filing

2026-04-28T14:04:05.000Z - 4 months ago

BioAffinity Technologies launches new study to expand use of CyPath lung tech

Apr 28, 2026, 9:16 AM EDT - 4 months ago

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment

Apr 14, 2026, 8:00 AM EDT - 4 months ago

New Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy

Apr 8, 2026, 7:00 PM EDT - 4 months ago

bioAffinity Technologies Transcript: Status update

Apr 7, 2026, 8:00 AM EDT - 4 months ago

bioAffinity Technologies' CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16

Apr 1, 2026, 8:00 AM EDT - 5 months ago

bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

Mar 26, 2026, 8:00 AM EDT - 5 months ago

bioAffinity Technologies Slides: Investor presentation

Mar 25, 2026, 8:00 AM EDT - 5 months ago

bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice

Mar 17, 2026, 7:45 AM EDT - 5 months ago

New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures

Mar 16, 2026, 8:00 AM EDT - 5 months ago

bioAffinity Technologies Proxy statement: Proxy Filing

Mar 13, 2026, 8:00 AM EDT - 5 months ago

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

Mar 13, 2026, 8:00 AM EDT - 5 months ago

bioAffinity Technologies Annual report: Q4 2025

Mar 13, 2026, 8:00 AM EDT - 5 months ago

bioAffinity Technologies Earnings release: Q4 2025

Mar 10, 2026, 7:47 AM EDT - 5 months ago

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

Mar 5, 2026, 7:00 AM EST - 6 months ago

bioAffinity Technologies Proxy statement: Proxy Filing

Mar 3, 2026, 8:30 AM EST - 6 months ago

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

Feb 25, 2026, 8:30 AM EST - 6 months ago

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

Feb 19, 2026, 11:00 AM EST - 6 months ago

New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer

Feb 17, 2026, 8:00 AM EST - 6 months ago

Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study

Feb 9, 2026, 8:00 AM EST - 7 months ago

bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

Jan 7, 2026, 8:00 AM EST - 8 months ago

bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

Dec 3, 2025, 8:00 AM EST - 9 months ago

bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

Nov 14, 2025, 8:30 AM EST - 10 months ago

bioAffinity Technologies Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 10 months ago

bioAffinity Technologies Earnings release: Q3 2025

Nov 14, 2025, 8:00 AM EST - 10 months ago

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 10 months ago

bioAffinity Technologies Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 10 months ago

bioAffinity Technologies Proxy statement: Proxy Filing

Nov 5, 2025, 8:00 AM EST - 10 months ago

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

Oct 28, 2025, 8:00 AM EDT - 10 months ago

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

Oct 27, 2025, 8:00 AM EDT - 10 months ago

bioAffinity Technologies Proxy statement: Proxy Filing

Oct 20, 2025, 8:00 AM EDT - 11 months ago

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

Oct 16, 2025, 8:00 AM EDT - 11 months ago

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

Oct 15, 2025, 8:00 AM EDT - 11 months ago

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

Oct 9, 2025, 2:00 PM EDT - 11 months ago

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 9, 2025, 1:00 PM EDT - 11 months ago

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 4:15 PM EDT - 11 months ago

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 3:45 PM EDT - 11 months ago

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 8:00 AM EDT - 11 months ago

bioAffinity Technologies Proxy statement: Proxy Filing

Oct 7, 2025, 8:00 AM EDT - 11 months ago

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

Sep 30, 2025, 12:44 PM EDT - 11 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

Sep 30, 2025, 12:15 PM EDT - 11 months ago

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

Sep 29, 2025, 5:59 PM EDT - 11 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

Sep 29, 2025, 3:51 PM EDT - 11 months ago

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

Lyn30 Aug. 24 at 2:47 PM

$BIAF OS 592k post split Time to

0 · Reply

Green_backs Aug. 24 at 2:47 PM

$BIAF this thing is so under valued. Already the same revenue as all of last year before the new deal

0 · Reply

vicdavis Aug. 24 at 2:21 PM

$BIAF A turd at any price smells as bad

0 · Reply

rihtim Aug. 24 at 1:47 PM

$BIAF AvMEDICAL ile yeni bir dağıtım anlaşması aracılığıyla federal sağlık kurumlarında CyPath® akciğer erişimini genişletiyor.

0 · Reply

rihtim Aug. 24 at 1:46 PM

0 · Reply

rihtim Aug. 24 at 1:45 PM

$BIAF A big congratulations to our outstanding team as they wrap up #AABIP2026!

0 · Reply

rihtim Aug. 24 at 1:43 PM

$BIAF Kısa Pozisyon Alan Hisse Senedi Yüzdesi 0.28%

0 · Reply

STACKD0E Aug. 24 at 1:14 PM

$BIAF 👀

0 · Reply

AlwaysABullNeverABear Aug. 24 at 1:12 PM

$BIAF LFG

0 · Reply

DekmarTrades Aug. 24 at 1:04 PM

A lot of weird gap ups just happened. $GRML $VCIG $BIAF $INCR

1 · Reply

TwongStocks Aug. 24 at 11:28 AM

$BRCC $BIAF $GAME $GRML Are among the seven stocks with reverse splits today. Full details in the quoted post. Trading will resume at 9:00am ET with the RS in effect

0 · Reply

R_NW Aug. 22 at 8:50 PM

$BIAF is this the next $PFSA....., don't be greedy settle for 5X and move on.

0 · Reply

FreeBeerTomorrow Aug. 22 at 9:59 AM

$BIAF BioAffinity Technologies, Inc. (NASDAQ: BIAF) has a 1-for-15 reverse stock split scheduled to trade split-adjusted at the market open on Monday, August 24, 2026. Based on bioAffinity Technologies' (NASDAQ: BIAF) pre-split metrics and the 1-for-15 ratio, the estimated post-split float is approximately 538,000 to 561,000 shares.

0 · Reply

AlwaysABullNeverABear Aug. 22 at 9:59 AM

$BIAF why was this halted?

1 · Reply

Lyn30 Aug. 22 at 12:10 AM

$BIAF OS 592k post split This stock have history of run like crazy . I always like this stock for products Whoever shorted imo most may be ducked soon.

0 · Reply

TwongStocks Aug. 21 at 8:19 PM

Seven reverse splits on Monday. Six on NASDAQ and one on the NYSE American. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am Friday morning. Split into two parts. Part 1 of 2: $BRCC 1 for 10. Will reduce outstanding Class A shares from approx 119.82m to approx 11.98m. $BIAF 1 for 15. Will reduce outstanding shares from approx 8.89m to approx 592k. $GAME 1 for 8. Will reduce outstanding shares from approx 102.27m to approx 12.78m. $GRML 1 for 50. Will reduce outstanding shares from approx 158.85m to approx 3.18m.

1 · Reply

Luckyizme Aug. 21 at 3:24 PM

$BIAF Looking for a pump eod, or will it be after

0 · Reply

AlwaysABullNeverABear Aug. 21 at 3:08 PM

$BIAF I need to get out here 🤣

0 · Reply

AlwaysABullNeverABear Aug. 20 at 8:01 PM

$BIAF come on!!!! Now!!!

0 · Reply

TwongStocks Aug. 20 at 7:45 PM

$BIAF Equity Corporate Actions Alert #2026 - 592 Information Regarding the Reverse Stock Split and CUSIP Number Change for bioAffinity Technologies, Inc. (BIAF) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-592 bioAffinity Technologies, Inc. (BIAF) will effect a one-for-fifteen (1-15) reverse split of its Common Stock. The reverse stock split will become effective on Monday, August 24, 2026. In conjunction with the reverse split, the CUSIP number will change to 09076W406.

1 · Reply

MoneyMacG Aug. 20 at 7:23 PM

$ZENA $QMCO $LEU $BIAF $BTSG I

0 · Reply

Slick1194 Aug. 20 at 6:59 PM

$BIAF after the split, there will be lots to short again...

2 · Reply

Market Cap	3.24M
Revenue (ttm)	6.16M
Net Income (ttm)	-14.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-242.05%
Debt to Equity Ratio	0.02

Volume	124,548
Avg Vol	4,016,766
Day's Range	N/A - N/A
Shares Out	8.10M
Stochastic %K	31%
Beta	-1.05
Analysts	Strong Buy
Price Target	$6.00